Experience with the enzyme substitution therapy in mucopolysaccharidosis;Skúsenosti s enzýmovou substitučnou liečbou u mukopolysacharidózy

Cesko-Slovenska Pediatrie

Volumn 61, Issue 10, 2006, Pages 593-598

  Hlavatá, Anna ^a   Kovacs L ^a  

^a DFNsP ^*  (Slovakia)

Author keywords

Enzyme substitution therapy; Fabry disease; Gaucher diseases; Lysosomal diseases; Mucopolysaccharidosis type I and type VI; Pompe disease

Indexed keywords

LARONIDASE;

ARTICLE; CASE REPORT; ENZYME REPLACEMENT; FEMALE; HUMAN; HURLER SYNDROME; MOTOR DEVELOPMENT; MUCOPOLYSACCHARIDOSIS; NEUROPATHY; SCHOOL CHILD; SELF MEDICATION; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 33750204361     PISSN: 00692328     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J. Med. Genet. 2001;38:769-775.
2. Walkley SU. The mucopolysaccharidoses. In: Zimran A. (ed). Glycolipid Storage Disorders. UK: Adis International Ltd., 2004:101-111.
3. Ďurovčíková D, Hlavatá A, Kováčová V, Poupětová H, Hrubá E, Kožich V. Klinicko-genetické skúsenosti s diagnostikou mukopolysacharidóz. Čes.-slov. Pediat. 1998;53:403-406.
4. Kakkis ED, Muenzer J, Tiller G, Waber L, Belmont J, Passage M. Enzyme replacement therapy in mukopolysaccharidosis. N. Engl. J. Med. 2001;344:182-188.
5. Elstein D, Abrahamov A, Hadas-Halpern I, Zimran A. Gaucher's disease. Lancet. 2001;358:324-327.
6. Barranger JA, O'Rourke E. Lessons learned from the development of enzyme therapy for Gaucher disease. J. Inherit. Metab. Dis. 2001;24(Suppl. 2):89-96.
7. Sachdev B, Takenaka T, Teraguchi H. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation. 2002;105:1407-1411.
8. Eng CM, Banikazemi M, Gordon RE. A phase I/II clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies. Amer. J. Hum. Genet. 2001;68:711-722.
9. Harmatz P, Ketteridge D, et al. Direct comparison of measures of endurance, mobility, and joint function during enzym-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): Results after 48 weeks in a phase 2 Open-Label Clinical Study of Recombinant Human N-Acetylgalactosamine 4-Sulfatase. Pediatrics. 2005;115:681-749.
10. Št'astná S, Pešková K, Elleder M, Poupětová H, Hlavatá A, Mišovicová N. Glykogenóza typu II - infantilná forma (morbus Pompe) v české a slovenské populaci. Čes.-slov. Pediat. 2003;58:436-440.
11. Hagemans MLC, Winkel LPF, et al. Disease severity in children and adults with Pompe disease related to age and disease duratio. Neurology. 2005;64:2139-2141.